Application of insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of medicine for treating cystic hydatid disease

Abstract

The invention relates to the technical field of medicines for treating the hydatid disease, and particularly relates to application of an insulin-like growth factor 1 receptor inhibitor BMS536924 in preparation of a medicine for treating the cystic hydatid disease. The invention discloses the application of the BMS536924 in preparation of the medicine for treating the cystic hydatid disease for the first time. In-vivo and in-vitro experimental data shows that the BMS536924 is an efficient medicine molecule for resisting to the hydatid disease; the insulin-like growth factor 1 receptor inhibitor BMS536924 has remarkable treatment effects on the cystic hydatid disease, and the treatment effects are superior to those of an albendazole metabolite, i.e., albendazole sulfoxide; the medicine effect of the BMS536924 and ABZSO combined use is better than those of single administration of the BMS536924 and the ABZSO; and meanwhile, compared with the dosage of the single albendazole sulfoxide, the dosage of the BMS536924 combined albendazole is reduced by 1 / 4 to 1 / 2, so that the dosage and the drug resistance are greatly reduced, and a very good treatment effect is achieved.

Description

technical field [0001] The invention relates to the technical field of echinococcosis drugs, and relates to the application of an insulin-like growth factor 1 receptor inhibitor BMS536924 as a drug for treating cystic echinococcosis. Background technique [0002] Cystic Echinococcosis (CE) is caused by Echinococcus granulosus ( Echinococcus granulosus, Eg ) is a serious zoonotic parasitic disease caused by parasitizing the human body. It is a global neglected disease. In 2010, the World Health Organization reported that the disease will once again become an important public health problem, and it is necessary to strengthen prevention and develop new treatments way. The initial infection of the intermediate host with cystic echinococcosis is through oral infective eggs, and the hexaconidia are hatched in the stomach of the intermediate host, pass through the intestinal wall, and parasitize mainly in the liver. Due to the difficulty of controlling the source of infection a...

AI Technical Summary

Problems solved by technology

[0006] The present invention provides an insulin-like growth factor 1 receptor inhibitor BMS536924 as an application in the preparation of a drug for treating cystic echinococcosis, which overcomes the above-mentioned deficiencies in the prior art, and can supplement and solve the problem that there is no insulin-like growth factor 1 receptor inhibitor at present. There are related reports about the body inhibitor BMS536924 as a drug for the treatment of cystic echinococcosis; at the same time, benzimidazoles have poor intestinal absorption, need to be taken for a long time, and are prone to drug resistance, which leads to unsatisfactory therapeutic effects

Images